Cretostimogene for Bladder Cancer: BOND-003 Study Ramifications

6 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Mark D. Tyson, MD, of Mayo Clinic, discusses the role of cretostimogene grenadenorepvec in treating BCG-unresponsive NMIBC, with a focus on Cohort P of the BOND-003 trial. Dr. Tyson examines the comprehensive event-free survival outcomes, the streamlined administration process compared to earlier trials, and how the ongoing PIVOT-006 and CORE-008 trials are refining the use of cretostimogene grenadenorepvec.

#bladdercancer #urology #cancerresearch #oncology
Category
Oncology
Be the first to comment

Up Next